BC
NBIX icon

Brinker Capital’s Neurocrine Biosciences NBIX Stock Holding History

Brinker Capital’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		$1.9M Sell
15,577
-74
-0.5% -$8.18K 0.06% 312
2020
Q1 		$1.35M Buy
15,651
+3,456
+28% +$338K 0.05% 333
2019
Q4 		$1.31M Buy
12,195
+89
+0.7% +$9.32K 0.04% 419
2019
Q3 		$1.09M Buy
12,106
+1,703
+16% +$159K 0.04% 459
2019
Q2 		$878K Buy
10,403
+51
+0.5% +$4.19K 0.03% 521
2019
Q1 		$912K Buy
10,352
+483
+5% +$40.4K 0.03% 492
2018
Q4 		$705K Buy
+9,869
New +$946K 0.03% 506

Other funds holding NBIX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Brinker Capital's NBIX Position: Q2 2020 in Review

Brinker Capital reduced its Neurocrine Biosciences (NBIX) stake by 0.47% in Q2 2020, selling an estimated $8.18K and leaving 15,577 shares worth $1.9M. The position accounts for 0.06% of the portfolio, ranked #312.

Brinker Capital first reported a position in NBIX in Q4 2018 and has held it in 7 quarters since. 419 funds tracked by Wall St. Rank hold NBIX as of Q2 2020.

  • Brinker Capital held 15,577 shares of Neurocrine Biosciences worth $1.9M as of Q2 2020.
  • Brinker Capital sold 74 Neurocrine Biosciences shares in Q2 2020, an estimated $8.18K.
  • Neurocrine Biosciences made up 0.06% of Brinker Capital's portfolio in Q2 2020, its #312 holding.
  • Brinker Capital first reported a position in Neurocrine Biosciences in Q4 2018 and has held it in 7 quarters since.
  • 419 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2020.

Based on Brinker Capital's 13F filing for Q2 2020, filed 30 Jul 2020.